Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety study of oral BCX9930 in paroxysmal nocturnal hemoglobinuria
2020-000501-93Phase 2Unknown
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vimircopan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by BioCryst Pharmaceuticals, Inc. Primary endpoint: Safety and tolerability. Status: unknown.
02
Drugs
vimircopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2020-000501-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000501-93.